BioSpace News Archive

Organizations representing millions of patients diagnosed with serious health conditions urge the U.S. Senate to immediately pass the U.S. House-approved coronavirus bill and take additional critical steps..

OTTAWA , March 16, 2020 /CNW/ - COVID-19 is a rapidly evolving global issue. The Government of Canada will do everything necessary to protect the health, safety, and wellbeing of Canadians, and is working around the clock to limit the spread of this pandemic. This is a critical time, and our top priority remains the safety and security of all Canadians. The Prime Minister,

Steinberg Diagnostic Medical Imaging continues their commitment to the Las Vegas valley by caring for patients that have not been directly affected by COVID-19.

More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA‑1 Phase 3 clinical trial Cash position of €73.2 million ($82.2 million) at the end of 2019 LYON, France and CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported

As part of our ongoing and aggressive commitment to address the coronavirus outbreak, the FDA updated a policy originally issued on Feb. 29 on diagnostic testing for coronavirus in order to achieve more rapid testing capacity in the U.S.

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company

Only High-Throughput System to Enable Simultaneous Testing for SARS-CoV-2 and Other Common Respiratory Viruses, Boosting Efficiency and Increasing Clinical Insight

Helix BioPharma Corp., a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced its financial results for the fiscal second quarter ended January 31, 2020.

Samsung Biologics entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer’s disease, which are all currently incurable.